Two Cases of Sarcoma Arising in Giant Cell Tumor of Bone Treated with Denosumab
Open Access
- 22 December 2015
- journal article
- case report
- Published by Hindawi Limited in Case Reports in Medicine
- Vol. 2015, 1-6
Abstract
Giant cell tumor (GCT) of bone is a generally benign, but often locally aggressive, neoplasm of bone, with a propensity for recurrence. Sarcomatous transformation is rare and typically occurs with a history of recurrences and radiation treatment. Denosumab, an inhibitor of the RANK ligand involved in bone resorption in GCT, is increasingly used in treatment of recurrent or unresectable giant cell tumor of bone. We report two cases of sarcomatous transformation of GCT to osteosarcoma in patients receiving denosumab. One was a 59-year-old male with a 12-year history of GCT and multiple recurrences taking denosumab for 2.5 years. The second case was in a 56-year-old male with a seven-year history of GCT taking denosumab for six months. Review of the literature shows one case report of malignant transformation of GCT in a patient being treated with denosumab. As the use of denosumab for treatment of GCT will likely increase, larger, controlled studies are needed to ascertain whether denosumab may play a role in malignant transformation of giant cell tumor of bone.Keywords
This publication has 21 references indexed in Scilit:
- Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 studyThe Lancet Oncology, 2013
- Denosumab in patients with cancer and skeletal metastases: A systematic review and meta-analysisCancer Treatment Reviews, 2013
- Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of BoneClinical Cancer Research, 2012
- RANKL, denosumab, and giant cell tumor of boneCurrent Opinion in Oncology, 2012
- Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trialThe Lancet, 2012
- Recurrent Giant Cell Tumor of Long Bones: Analysis of Surgical ManagementClinical Orthopaedics and Related Research, 2011
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyThe Lancet, 2011
- Giant Cell Tumor of Bone: Risk Factors for RecurrenceClinical Orthopaedics and Related Research, 2010
- Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 studyThe Lancet Oncology, 2010
- Malignancy in giant cell tumor of boneCancer, 2003